PCN227 A PARTITIONED SURVIVAL MODEL TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.423
https://www.valueinhealthjournal.com/article/S1098-3015(19)32801-3/fulltext
Title :
PCN227 A PARTITIONED SURVIVAL MODEL TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32801-3&doi=10.1016/j.jval.2019.09.423
First page :
Section Title :
Open access? :
No
Section Order :
10352